ACTG175 {speff2trial}R Documentation

AIDS Clinical Trials Group Study 175

Description

ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human immunodeficiency virus type I whose CD4 cell counts were between 200 and 500 per cubic millimeter.

Usage

data(ACTG175)

Format

A data frame with 2139 observations on the following 24 variables:

pidnum
patient's ID number
age
age in years at baseline
wtkg
weight in kg at baseline
hemo
hemophilia (0=no, 1=yes)
homo
homosexual activity (0=no, 1=yes)
drugs
history of intravenous drug use (0=no, 1=yes)
karnof
Karnofsky score (on a scale of 0-100)
oprior
non-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)
z30
zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)
zprior
zidovudine use prior to treatment initiation (0=no, 1=yes)
preanti
number of days of previously received antiretroviral therapy
race
race (0=white, 1=non-white)
gender
gender (0=female, 1=male)
str2
antiretroviral history (0=naive, 1=experienced)
strat
antiretroviral history stratification (1='antiretroviral naive', 2='> 1 but <=q 52 weeks of prior antiretroviral therapy', 3='> 52 weeks')
symptom
symptomatic indicator (0=asymptomatic, 1=symptomatic)
treat
treatment indicator (0=zidovudine only, 1=other therapies)
offtrt
indicator of off-treatment before 96pm5 weeks (0=no,1=yes)
cd40
CD4 cell count at baseline
cd420
CD4 cell count at 20pm5 weeks
cd496
CD4 cell count at 96pm5 weeks (=NA if missing)
r
missing CD4 cell count at 96pm5 weeks (0=missing, 1=observed)
cd80
CD8 cell count at baseline
cd820
CD8 cell count at 20pm5 weeks.

Details

There are two treatment arms in the data set, zidovudine monotherapy and the mixture of all other study therapies. The data set includes the following post-randomization covariates: CD4 and CD8 cell count at 20pm5 weeks and the indicator of whether or not the patient was taken off-treatment before 96pm5 weeks.

References

Hammer SM, et al. (1996), "A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter.", New England Journal of Medicine, 335:1081–1090.


[Package speff2trial version 1.0.0 Index]